343 related articles for article (PubMed ID: 10400771)
1. Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs.
Harvey BG; Hackett NR; El-Sawy T; Rosengart TK; Hirschowitz EA; Lieberman MD; Lesser ML; Crystal RG
J Virol; 1999 Aug; 73(8):6729-42. PubMed ID: 10400771
[TBL] [Abstract][Full Text] [Related]
2. Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes.
Ben-Gary H; McKinney RL; Rosengart T; Lesser ML; Crystal RG
Mol Ther; 2002 Aug; 6(2):287-97. PubMed ID: 12349828
[TBL] [Abstract][Full Text] [Related]
3. Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions.
Harvey BG; Maroni J; O'Donoghue KA; Chu KW; Muscat JC; Pippo AL; Wright CE; Hollmann C; Wisnivesky JP; Kessler PD; Rasmussen HS; Rosengart TK; Crystal RG
Hum Gene Ther; 2002 Jan; 13(1):15-63. PubMed ID: 11779412
[TBL] [Abstract][Full Text] [Related]
4. Analysis of risk factors for local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions.
Crystal RG; Harvey BG; Wisnivesky JP; O'Donoghue KA; Chu KW; Maroni J; Muscat JC; Pippo AL; Wright CE; Kaner RJ; Leopold PL; Kessler PD; Rasmussen HS; Rosengart TK; Hollmann C
Hum Gene Ther; 2002 Jan; 13(1):65-100. PubMed ID: 11779413
[TBL] [Abstract][Full Text] [Related]
5. Host responses and persistence of vector genome following intrabronchial administration of an E1(-)E3(-) adenovirus gene transfer vector to normal individuals.
Harvey BG; Hackett NR; Ely S; Crystal RG
Mol Ther; 2001 Feb; 3(2):206-15. PubMed ID: 11237677
[TBL] [Abstract][Full Text] [Related]
6. "Sero-switch" adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype.
Mastrangeli A; Harvey BG; Yao J; Wolff G; Kovesdi I; Crystal RG; Falck-Pedersen E
Hum Gene Ther; 1996 Jan; 7(1):79-87. PubMed ID: 8825871
[TBL] [Abstract][Full Text] [Related]
7. Cellular immune responses of healthy individuals to intradermal administration of an E1-E3- adenovirus gene transfer vector.
Harvey BG; Worgall S; Ely S; Leopold PL; Crystal RG
Hum Gene Ther; 1999 Nov; 10(17):2823-37. PubMed ID: 10584928
[TBL] [Abstract][Full Text] [Related]
8. Acute responses of non-human primates to airway delivery of an adenovirus vector containing the human cystic fibrosis transmembrane conductance regulator cDNA.
Brody SL; Metzger M; Danel C; Rosenfeld MA; Crystal RG
Hum Gene Ther; 1994 Jul; 5(7):821-36. PubMed ID: 7526901
[TBL] [Abstract][Full Text] [Related]
9. Adenovirus-mediated gene transfer for cystic fibrosis: quantitative evaluation of repeated in vivo vector administration to the lung.
Yei S; Mittereder N; Tang K; O'Sullivan C; Trapnell BC
Gene Ther; 1994 May; 1(3):192-200. PubMed ID: 7584081
[TBL] [Abstract][Full Text] [Related]
10. Safety of direct myocardial administration of an adenovirus vector encoding vascular endothelial growth factor 121.
Patel SR; Lee LY; Mack CA; Polce DR; El-Sawy T; Hackett NR; Ilercil A; Jones EC; Hahn RT; Isom OW; Rosengart TK; Crystal RG
Hum Gene Ther; 1999 May; 10(8):1331-48. PubMed ID: 10365664
[TBL] [Abstract][Full Text] [Related]
11. Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype.
Mack CA; Song WR; Carpenter H; Wickham TJ; Kovesdi I; Harvey BG; Magovern CJ; Isom OW; Rosengart T; Falck-Pedersen E; Hackett NR; Crystal RG; Mastrangeli A
Hum Gene Ther; 1997 Jan; 8(1):99-109. PubMed ID: 8989999
[TBL] [Abstract][Full Text] [Related]
12. Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus.
Harvey BG; Leopold PL; Hackett NR; Grasso TM; Williams PM; Tucker AL; Kaner RJ; Ferris B; Gonda I; Sweeney TD; Ramalingam R; Kovesdi I; Shak S; Crystal RG
J Clin Invest; 1999 Nov; 104(9):1245-55. PubMed ID: 10545523
[TBL] [Abstract][Full Text] [Related]
13. Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. I. Methods, safety, and clinical implications.
Joseph PM; O'Sullivan BP; Lapey A; Dorkin H; Oren J; Balfour R; Perricone MA; Rosenberg M; Wadsworth SC; Smith AE; St George JA; Meeker DP
Hum Gene Ther; 2001 Jul; 12(11):1369-82. PubMed ID: 11485629
[TBL] [Abstract][Full Text] [Related]
14. Use of quantitative TaqMan real-time PCR to track the time-dependent distribution of gene transfer vectors in vivo.
Hackett NR; El Sawy T; Lee LY; Silva I; O'Leary J; Rosengart TK; Crystal RG
Mol Ther; 2000 Dec; 2(6):649-56. PubMed ID: 11124067
[TBL] [Abstract][Full Text] [Related]
15. Incidence and prevalence of neutralizing antibodies to the common adenoviruses in children with cystic fibrosis: implication for gene therapy with adenovirus vectors.
Piedra PA; Poveda GA; Ramsey B; McCoy K; Hiatt PW
Pediatrics; 1998 Jun; 101(6):1013-9. PubMed ID: 9606228
[TBL] [Abstract][Full Text] [Related]
16. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease.
Rosengart TK; Lee LY; Patel SR; Sanborn TA; Parikh M; Bergman GW; Hachamovitch R; Szulc M; Kligfield PD; Okin PM; Hahn RT; Devereux RB; Post MR; Hackett NR; Foster T; Grasso TM; Lesser ML; Isom OW; Crystal RG
Circulation; 1999 Aug; 100(5):468-74. PubMed ID: 10430759
[TBL] [Abstract][Full Text] [Related]
17. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo.
O'Riordan CR; Lachapelle A; Delgado C; Parkes V; Wadsworth SC; Smith AE; Francis GE
Hum Gene Ther; 1999 May; 10(8):1349-58. PubMed ID: 10365665
[TBL] [Abstract][Full Text] [Related]
18. Immune response to recombinant capsid proteins of adenovirus in humans: antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity.
Gahéry-Ségard H; Farace F; Godfrin D; Gaston J; Lengagne R; Tursz T; Boulanger P; Guillet JG
J Virol; 1998 Mar; 72(3):2388-97. PubMed ID: 9499099
[TBL] [Abstract][Full Text] [Related]
19. Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis.
Zabner J; Ramsey BW; Meeker DP; Aitken ML; Balfour RP; Gibson RL; Launspach J; Moscicki RA; Richards SM; Standaert TA
J Clin Invest; 1996 Mar; 97(6):1504-11. PubMed ID: 8617884
[TBL] [Abstract][Full Text] [Related]
20. Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: implications and proposals for human therapy.
Chen Y; Yu DC; Charlton D; Henderson DR
Hum Gene Ther; 2000 Jul; 11(11):1553-67. PubMed ID: 10945769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
